Skip to main content
Erschienen in: Pathology & Oncology Research 2/2012

01.04.2012 | Research

Expression of Hedgehog Pathway Components is Associated with Bladder Cancer Progression and Clinical Outcome

verfasst von: Hui-chan He, Jia-hong Chen, Xi-bin Chen, Guo-qiang Qin, Chao Cai, Yu-xiang Liang, Zhao-dong Han, Qi-shan Dai, Yan-ru Chen, Guo-hua Zeng, Jian-guo Zhu, Fu-neng Jiang, Wei-de Zhong

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Hedgehog (Hh) pathway has been implicated in the tumorigenesis of a large number of human tumors. But its effects on the progression and prognosis of bladder cancer remain poorly understood. The aim of this study was to investigate expression patterns of Hh pathway components in bladder cancer and to elucidate their prognostic values in this tumor. The expression of sonic hedgehog (Shh), its receptor Patched (Ptch1), and downstream transcription factor Gli1 in 118 specimens of bladder cancer and 30 specimens of adjacent normal bladder tissue was determined by immunohistochemistry. Statistical analyses were applied to test the relationship between the expression of these three proteins and clinicopathologic features and prognosis. Immunohistochemical staining results showed the localizations of Shh and Ptch1 proteins to be mainly located in the cytoplasm of bladder cancer cells, whereas Gli1 was mainly localized in the nuclear of tumor cells. Additionally, positive expression of Shh, Ptch1 and Gli1 proteins was correlated with pathological stage (P = 0.006, 0.006 and 0.008, respectively), venous invasion (P = 0.01, 0.01 and 0.012, respectively) and lymph node metastasis (P = 0.009, 0.01 and 0.013, respectively), but not with other factors including age, gender, tumor grade and recurrence of superficial cancer. Moreover, patients with positive expression of Shh, Ptch1 and Gli1 proteins respectively showed poorer disease-free (P = 0.002, 0.002 and 0.001, respectively) and overall survival (all P < 0.001) than those with negative expression of these three proteins. Univariate and multivariate analysis of prognostic factors in bladder cancer patients indicated that the expression patterns of Shh, Ptch1 and Gli1 proteins were independent unfavorable prognostic factors (all P < 0.001). This is the first report describing about the correlation between Hh pathway and the prognosis of bladder cancer. Expression of Shh, Ptch1 and Gli1 proteins was greater in bladder cancers than in the adjacent normal tissues. The examination of their expression is potentially valuable in prognostic evaluation of bladder cancer.
Literatur
1.
Zurück zum Zitat Kramer MW, Escudero DO, Lokeshwar SD et al (2011) Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer 117:1197–209PubMedCrossRef Kramer MW, Escudero DO, Lokeshwar SD et al (2011) Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer 117:1197–209PubMedCrossRef
2.
Zurück zum Zitat Lei Y, Yan S, Ming-De L et al (2011) Prognostic significance of Aurora-A expression in human bladder cancer. Acta Histochem 113:514–518PubMedCrossRef Lei Y, Yan S, Ming-De L et al (2011) Prognostic significance of Aurora-A expression in human bladder cancer. Acta Histochem 113:514–518PubMedCrossRef
3.
Zurück zum Zitat Canesin G, Gonzalez-Peramato P, Palou J et al (2010) Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 31:277–285PubMedCrossRef Canesin G, Gonzalez-Peramato P, Palou J et al (2010) Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 31:277–285PubMedCrossRef
4.
Zurück zum Zitat Pasca di Magliano M, Hebrok M (2003) Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 3:903–911PubMedCrossRef Pasca di Magliano M, Hebrok M (2003) Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 3:903–911PubMedCrossRef
5.
Zurück zum Zitat Kameda C, Tanaka H, Yamasaki A (2009) The Hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer. Anticancer Res 29:871–879PubMed Kameda C, Tanaka H, Yamasaki A (2009) The Hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer. Anticancer Res 29:871–879PubMed
6.
Zurück zum Zitat Lauth M, Toftgrd R (2007) The Hedgehog pathway as a drug target in cancer therapy. urr Opin Investig. Drugs 8:457–461 Lauth M, Toftgrd R (2007) The Hedgehog pathway as a drug target in cancer therapy. urr Opin Investig. Drugs 8:457–461
7.
Zurück zum Zitat Laurendeau I, Ferrer M, Garrido D (2010) Gene expression profiling of the Hedgehog signaling pathway in human meningiomas. Mol Med 16:262–270PubMedCrossRef Laurendeau I, Ferrer M, Garrido D (2010) Gene expression profiling of the Hedgehog signaling pathway in human meningiomas. Mol Med 16:262–270PubMedCrossRef
8.
Zurück zum Zitat Walter K, Omura N, Hong SM (2010) Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. Clin Cancer Res 16:1781–1789PubMedCrossRef Walter K, Omura N, Hong SM (2010) Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. Clin Cancer Res 16:1781–1789PubMedCrossRef
9.
Zurück zum Zitat Berman DM, Karhadkar SS, Maitra A (2003) Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425:846–851PubMedCrossRef Berman DM, Karhadkar SS, Maitra A (2003) Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425:846–851PubMedCrossRef
10.
Zurück zum Zitat Ma X, Chen K, Huang S (2005) Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis 26:1698–705PubMedCrossRef Ma X, Chen K, Huang S (2005) Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis 26:1698–705PubMedCrossRef
11.
Zurück zum Zitat Thayer SP, di Magliano MP, Heiser PW (2003) Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425:851–856PubMedCrossRef Thayer SP, di Magliano MP, Heiser PW (2003) Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425:851–856PubMedCrossRef
12.
Zurück zum Zitat Yanai K, Nagai S, Wada J (2007) Hedgehog signaling pathway is a possible therapeutic target for gastric cancer. J SurgOncol 95:55–62 Yanai K, Nagai S, Wada J (2007) Hedgehog signaling pathway is a possible therapeutic target for gastric cancer. J SurgOncol 95:55–62
13.
Zurück zum Zitat Chen G, Goto Y, Sakamoto R et al (2011) GLI1, a crucial mediator of sonic hedgehog signaling in prostate cancer, functions as a negative modulator for androgen receptor. Biochem Biophys Res Commun 404:809–815PubMedCrossRef Chen G, Goto Y, Sakamoto R et al (2011) GLI1, a crucial mediator of sonic hedgehog signaling in prostate cancer, functions as a negative modulator for androgen receptor. Biochem Biophys Res Commun 404:809–815PubMedCrossRef
14.
Zurück zum Zitat Kelleher FC. Hedgehog signalling and therapeutics in pancreatic cancer. Carcinogenesis. 2010 In press Kelleher FC. Hedgehog signalling and therapeutics in pancreatic cancer. Carcinogenesis. 2010 In press
15.
Zurück zum Zitat Chen M, Hildebrandt MA, Clague J et al (2010) Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prev Res (Phila) 3:1235–1245CrossRef Chen M, Hildebrandt MA, Clague J et al (2010) Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prev Res (Phila) 3:1235–1245CrossRef
16.
Zurück zum Zitat Greene FL, Balch CM, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. AJCC Springer-Verlag, New York, pp 335–340 Greene FL, Balch CM, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. AJCC Springer-Verlag, New York, pp 335–340
17.
Zurück zum Zitat Oue T, Yoneda A, Uehara S et al (2010) Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. J Pediatr Surg 45:387–392PubMedCrossRef Oue T, Yoneda A, Uehara S et al (2010) Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. J Pediatr Surg 45:387–392PubMedCrossRef
18.
Zurück zum Zitat Brown RS, Wahl RL (1993) Overexpression of Glut-1 glucose transporter in human breast cancer: an immunohistochemical study. Cancer 72:2979–2985PubMedCrossRef Brown RS, Wahl RL (1993) Overexpression of Glut-1 glucose transporter in human breast cancer: an immunohistochemical study. Cancer 72:2979–2985PubMedCrossRef
19.
Zurück zum Zitat Ju B, Spitsbergen J, Eden CJ et al (2009) Co-activation of hedgehog and AKT pathways promote tumorigenesis in zebrafish. Mol Cancer 8:40PubMedCrossRef Ju B, Spitsbergen J, Eden CJ et al (2009) Co-activation of hedgehog and AKT pathways promote tumorigenesis in zebrafish. Mol Cancer 8:40PubMedCrossRef
20.
Zurück zum Zitat Ingham PW, McMahon AP (2001) Hedgehog signaling in animal development: paradigms and principles. Genes Dev 15:3059–3087PubMedCrossRef Ingham PW, McMahon AP (2001) Hedgehog signaling in animal development: paradigms and principles. Genes Dev 15:3059–3087PubMedCrossRef
21.
Zurück zum Zitat Merchant JL, Saqui-Salces M, El-Zaatari M (2010) Hedgehog signaling in gastric physiology and cancer. Prog Mol Biol Transl Sci 96:133–156PubMedCrossRef Merchant JL, Saqui-Salces M, El-Zaatari M (2010) Hedgehog signaling in gastric physiology and cancer. Prog Mol Biol Transl Sci 96:133–156PubMedCrossRef
22.
Zurück zum Zitat Morton JP, Mongeau ME, Klimstra DS (2007) Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci USA 104:5103–5108PubMedCrossRef Morton JP, Mongeau ME, Klimstra DS (2007) Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci USA 104:5103–5108PubMedCrossRef
23.
Zurück zum Zitat Berman DM, Karhadkar SS, Maitra A (2003) Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumors. Nature 425:846–851PubMedCrossRef Berman DM, Karhadkar SS, Maitra A (2003) Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumors. Nature 425:846–851PubMedCrossRef
24.
Zurück zum Zitat Rush SZ, Abel TW, Valadez JG et al (2010) Activation of the Hedgehog pathway in pilocytic astrocytomas. Neuro Oncol 12:790–798PubMedCrossRef Rush SZ, Abel TW, Valadez JG et al (2010) Activation of the Hedgehog pathway in pilocytic astrocytomas. Neuro Oncol 12:790–798PubMedCrossRef
25.
Zurück zum Zitat Liao X, Siu MK, Au CW et al (2009) Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis 30:131–140PubMedCrossRef Liao X, Siu MK, Au CW et al (2009) Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis 30:131–140PubMedCrossRef
26.
Zurück zum Zitat Yang Y, Tian X, Xie X et al (2010) Expression and regulation of hedgehog signaling pathway in pancreatic cancer. Langenbecks Arch Surg 395:515–525PubMedCrossRef Yang Y, Tian X, Xie X et al (2010) Expression and regulation of hedgehog signaling pathway in pancreatic cancer. Langenbecks Arch Surg 395:515–525PubMedCrossRef
Metadaten
Titel
Expression of Hedgehog Pathway Components is Associated with Bladder Cancer Progression and Clinical Outcome
verfasst von
Hui-chan He
Jia-hong Chen
Xi-bin Chen
Guo-qiang Qin
Chao Cai
Yu-xiang Liang
Zhao-dong Han
Qi-shan Dai
Yan-ru Chen
Guo-hua Zeng
Jian-guo Zhu
Fu-neng Jiang
Wei-de Zhong
Publikationsdatum
01.04.2012
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2012
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-011-9451-2

Weitere Artikel der Ausgabe 2/2012

Pathology & Oncology Research 2/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.